Advertisement

Topics

Catalent to Acquire Juniper Pharmaceuticals for $133 Million

09:29 EDT 5 Jul 2018 | Speciality Pharma Journal

SOMERSET, N.J.–(BUSINESS WIRE)–Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has agreed to acquire Juniper Pharmaceuticals, Inc. (NASDAQ: JNPR), including its Nottingham, U.K.-based Juniper Pharma Services division. When combined with Catalent’s existing industry-leading drug development and manufacturing capabilities …

Original Article: Catalent to Acquire Juniper Pharmaceuticals for $133 Million

NEXT ARTICLE

More From BioPortfolio on "Catalent to Acquire Juniper Pharmaceuticals for $133 Million"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...